Holen Sie sich die Stockscreener-App
26.20
13.43%
3.05
Schlusskurs vom Vortag:
$23.15
Offen:
$27.29
24-Stunden-Volumen:
1.72M
Relative Volume:
0.55
Marktkapitalisierung:
$1.63B
Einnahmen:
$14.34M
Nettoeinkommen (Verlust:
$-199.00M
KGV:
-6.6837
EPS:
-3.92
Netto-Cashflow:
$-183.51M
1W Leistung:
+12.27%
1M Leistung:
+26.37%
6M Leistung:
+76.60%
1J Leistung:
+64.95%
1-Tages-Spanne:
$25.95
$28.77
1-Wochen-Bereich:
$22.11
$28.77
52-Wochen-Spanne:
$7.76
$71.50
Uniqure N V Stock (QURE) Company Profile
Firmenname
Uniqure N V
Sektor
Branche
Telefon
1-339-970-7000
Adresse
PAASHEUVELWEG 25A, AMSTERDAM
Vergleichen Sie QURE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
26.21 | 1.44B | 14.34M | -199.00M | -183.51M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.17 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
810.41 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
407.74 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
811.40 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.73 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-04 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-08-14 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-04-01 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2024-12-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-02-29 | Herabstufung | Goldman | Buy → Neutral |
| 2023-12-19 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-17 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-21 | Eingeleitet | UBS | Neutral |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-01 | Hochstufung | Mizuho | Neutral → Buy |
| 2021-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-11-11 | Eingeleitet | Berenberg | Buy |
| 2020-11-09 | Eingeleitet | Jefferies | Buy |
| 2020-11-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-08-25 | Eingeleitet | Raymond James | Strong Buy |
| 2020-07-31 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-06-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Eingeleitet | Cowen | Outperform |
| 2019-12-03 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Eingeleitet | Credit Suisse | Outperform |
| 2019-10-11 | Eingeleitet | Stifel | Buy |
| 2019-09-25 | Eingeleitet | Bernstein | Outperform |
| 2019-09-12 | Eingeleitet | Mizuho | Buy |
| 2019-07-30 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-07-08 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-03-29 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Uniqure N V Aktie (QURE) Neueste Nachrichten
uniQure (QURE) Surges on FDA Meeting for Gene Therapy Approval - GuruFocus
UniQure Announces FDA Type A Meeting To Discuss BLA Data For Huntington's Gene Therapy - Nasdaq
US-listed shares of uniQure rise 13% premarket as FDA review talks revive hopes for Huntington's therapy - MarketScreener
uniQure's (QURE) Gene Therapy for Huntington's Disease Advances with FDA Meeting - GuruFocus
uniQure gains as FDA sets up meeting on gene therapy (QURE:NASDAQ) - Seeking Alpha
uniQure prepares for FDA Type A meeting on AMT-130 - TipRanks
uniQure stock soars after FDA meeting scheduled on Huntington’s therapy By Investing.com - Investing.com UK
uniQure schedules FDA meeting to discuss accelerated approval for HD therapy - Investing.com India
uniQure Announces Type A Meeting Scheduled with FDA - The Manila Times
uniQure N.V. Schedules FDA Meeting for AMT-130 Approval - TradingView — Track All Markets
FDA to review data on experimental Huntington's gene therapy at uniQure - Stock Titan
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - PR Newswire
uniQure: Now What? (NASDAQ:QURE) - Seeking Alpha
How sustainable is uniQure N.V. stock dividend payout2025 Growth vs Value & Weekly Market Pulse Alerts - ulpravda.ru
Pullback Watch: Is uniQure N.V. stock attractive for long term wealth building2025 Market Outlook & Weekly Hot Stock Watchlists - ulpravda.ru
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - GlobeNewswire Inc.
How (QURE) Movements Inform Risk Allocation Models - Stock Traders Daily
QURE Investigation: Investors Encouraged to Contact Kirby McInerney LLP - Business Wire
Wells Fargo Maintains UniQure NV(QURE.US) With Buy Rating, Cuts Target Price to $60 - 富途牛牛
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - FinancialContent
uniQure (NASDAQ:QURE) Upgraded at Wall Street Zen - MarketBeat
QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire
uniQure N.V. (QURE) Stock Analysis: Unveiling a 131% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
How reliable is uniQure NV UQ1 stock dividend growth2025 Big Picture & Technical Pattern Based Buy Signals - moha.gov.vn
QURE Investigation Reminder: Kessler Topaz Meltzer & Check, - GlobeNewswire
QURE Investigation Notice: Kessler Topaz Meltzer & Check, LLP En - GuruFocus
QURE Investigation Notice: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - PR Newswire
QURE INVESTIGATION REMINDER: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire
Whittier Daily News - FinancialContent
Understanding Momentum Shifts in (QURE) - Stock Traders Daily
uniQure N.V. (NASDAQ:QURE) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
uniQure N.V. (NASDAQ:QURE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
uniQure (NASDAQ:QURE) Trading 5.4% HigherWhat's Next? - MarketBeat
Gene therapy genie back in the bottle? - BioWorld MedTech
uniQure Notice of Investigation: Kessler Topaz Meltzer & - GlobeNewswire
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourage - GuruFocus
uniQure (NASDAQ:QURE) Trading Down 4.6%Here's Why - MarketBeat
Cell And Gene Therapy Leaders See Transformative Results Outweighing Industry Setbacks - Citeline News & Insights
What do analysts think about UniQure (QURE)? - MSN
What Do Analysts Think About UniQure (QURE)? - Finviz
How uniQure N.V. stock benefits from tech adoptionJuly 2025 Closing Moves & Fast Moving Stock Watchlists - Улправда
Quarterly Earnings: How uniQure N.V. stock benefits from tech adoptionJuly 2025 Setups & Reliable Breakout Forecasts - Улправда
Is uniQure N.V. stock positioned for long term growthLong Setup & Growth-Oriented Investment Plans - ulpravda.ru
What hedge fund moves indicate for uniQure N.V. (UQ1) stockJuly 2025 Breakouts & AI Powered Buy/Sell Recommendations - Улправда
Revisiting UniQure (NASDAQ:QURE) - Seeking Alpha
uniQure: Why Waiting For Clarity Beats Chasing The Next Step Jump (NASDAQ:QURE) - Seeking Alpha
uniQure (NASDAQ:QURE) Shares Up 14%What's Next? - MarketBeat
Sanders Morris Harris LLC Makes New $5.08 Million Investment in uniQure N.V. $QURE - MarketBeat
Revenue per share of uniQure N.V. – LSX:A1XDTV - TradingView — Track All Markets
What's Going On With uniQure Stock On Tuesday? - Benzinga
uniQure (NASDAQ:QURE) Shares Gap UpWhat's Next? - MarketBeat
Finanzdaten der Uniqure N V-Aktie (QURE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Uniqure N V-Aktie (QURE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Gut Robert | Director |
Nov 06 '25 |
Sale |
27.26 |
31,434 |
856,881 |
40,145 |
| Kaye Jack | Director |
Nov 04 '25 |
Option Exercise |
9.88 |
38,810 |
383,535 |
38,249 |
| Kaye Jack | Director |
Nov 04 '25 |
Sale |
30.34 |
38,810 |
1,177,517 |
20,439 |
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):